Roche Palo Alto LLC
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
49
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 7, 2027The maintenance fee for Isoxazolo-Pyridine Derivatives (US 9,073,908) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists (US 9,173,861) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
Recent changes
- 2 terms have ended since Aug 23, 2026
- Aug 25 US 8,524,725 Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases · term ended
- Aug 25 US 7,531,547 Diaminopyrimidines as P2X3 and P2X2/3 modulators · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,491,821 | Inhibitors of P2X3 In force · USPTO record | In force | USPTO record | |
| US 8,349,572 | Stable cell lines expressing hERG In force · USPTO record | In force | USPTO record | |
| US 7,625,949 | Methods for treating retroviral infections In force · USPTO record | In force | USPTO record | |
| US 7,595,405 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists In force · USPTO record | In force | USPTO record | |
| US 8,193,368 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists In force · USPTO record | In force | USPTO record | |
| US 10,201,525 | Tetrazole-Substituted Arylamides as PX2 and PX2/3 Antagonists In force · Low confidence | In force | Low confidence | |
| US 7,776,590 | Stable cell lines expressing hERG In force · USPTO record | In force | USPTO record | |
| US 7,858,632 | Diaminopyrimidines as P2X3 and P2X2/3 Antagonists In force · High confidence | In force | High confidence | |
| US 8,580,960 | Process for synthesis of phenoxy diaminopyrimidine derivatives In force · USPTO record | In force | USPTO record | |
| US 9,643,934 | Process for synthesis of phenoxy diaminopyrimidine derivatives In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 50: 3 patents in force now held by others · 258 lapsed for an unpaid fee · 69 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 17 abandoned · 58 no status recorded